Rivaroxaban Scores High Marks for Acute DVT : 'Results from EINSTEIN-DVT could transform the way physicians treat deep vein thrombosis.'

Dr. Büller disclosed having received research grants and serving as a consultant to Bayer Schering Pharma, which sponsored the EINSTEIN-DVT trial. Dr. Darius declared no financial conflicts.

Recurrent venous thromboembolism occurred in 2.1% of the rivaroxaban group, vs. 3.0% of those on standard therapy.

Source DR. BÜLLER